Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cream aims to fade dark spots naturally

NCT ID NCT05986123

Symptom relief Sponsor: USMARI Research & Innovation Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a cream made from natural plant extracts, niacinamide, and arbutin to see if it safely lightens dark spots (post-inflammatory hyperpigmentation) on the skin. Twenty-five healthy Malaysian adults used the cream twice daily for 20 weeks. Researchers measured changes in skin spots and checked for side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Topical cream containing niacinamide, arbutin, Scutellaria Baicalensis Root Extract, Centella Asiatica Extract, and Camellia Sinensis Leaf Extract
What this could lead to
If it works, this could offer a safe, natural option for fading dark spots left after skin injuries or inflammation.
What could go wrong
This was a small, completed study with only 25 healthy adults, so results may not apply to everyone. The cream is cosmetic and not a treatment for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

25 people

The number who actually took part.

Started

Nov 2023

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Malaysia citizen * Healthy adult, aged between 18 to 40 years old. * Participants who have post-inflammatory hyperpigmentation on skin Exclusion Criteria: * Participants with skin disorders such as skin infection or skin inflammation. * Participants who have undergone any skin and cosmetic treatments such as dermal fillers, botox, laser, chemical peels within the last 3 months. * Participant who is taking isotretinoin for the past 6 or 12 months and immunocompromised patients. * Pregnant, breastfeeding women or planned for pregnancy during the study period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hyperpigmentation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy

Contacts and locations

Locations

  • Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre

    Petaling Jaya, Selangor, 47810, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.